Yahoo Japan’s YJ Capital unit was among the investors in a $27.9m round for the blockchain technology provider that will go to improving its products and hiring talent.
Month: June 2020
Wasabi wraps up $30m round
NTT Docomo-backed Wasabi plans to use the proceeds from the $30m round to expand its hot cloud storage service in international markets.
Loom weaves new series B funding
Video messaging platform developer Loom, which counts Slack as an investor, closed a $28.8m round that reportedly doubled its valuation to $350m.
Syapse signs off on $30m round
Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance and Ascension Ventures all took part in the cancer data provider’s latest round.
Principle Power gets $22m Tokyo Gas influx
Offshore wind technology developer Principle received funding from Tokyo Gas, which joined existing investors including EDP Ventures, Repsol and ASM Industries.
Participating for the many not the few
It is a good question from the innovation manager at a large global 1000 corporation…
Didi Chuxing’s autonomous driving spinoff draws $500m
SoftBank Vision Fund 2 has led a $500m funding round for the driverless vehicle software developer, which is based on work by Didi Chuxing going back to 2016.
Yanmade reveals IPO plans
The Legend Capital-backed industrial testing technology provider has filed to raise up to $98.8m when it floats on Shanghai’s Star Market.
Gingko traces Illumina for $70m round
Illumina, General Atlantic and Viking Global Investors supplied $70m for Ginkgo Bioworks, a cell programming technology provider that has now raised more than $789m altogether.
SmartRent opens up for $60m series C
Amazon Alexa Fund contributed to the home automation technology producer’s series C round through its Alexa Fund, revealing itself as an existing investor in the process.
Synack snatches $52m in series D round
Existing investors Hewlett Packard Enterprise, GV, Intel Capital, SingTel Innov8 and M12 all participated as the cybersecurity services provider took its total funding to $112m.
Palvella packs in $45m
Existing backer Ligand took part in a series C round that will fund late-stage clinical trials for Palvella Therapeutics’ rare genetic disease drug candidates.
Q32 Bio cooks up $46m series A
Q32 Bio has launched with $46m from investors including Sanofi Ventures and Children’s Hospital Colorado to target autoimmune and inflammatory diseases.
Livzon attends to Atom in $30m round
Atom Bioscience will use the capital from the series B round, which was co-led by Livzon Pharmaceutical, to advance its gout treatment into phase 2 trials.